Molecular characterisation of neonatal cardiac hypertrophy and its regression

Cardiology in the Young

Volumn 14, Issue 5, 2004, Pages 498-505

  Gopinath, Bamini ^a   Trent, Ronald J ^a   Yu, Bing ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Diabetes; Gene expression; Left ventricular hypertrophy; Real time polymerase chain reaction

Indexed keywords

ACTIN; ATRIAL NATRIURETIC FACTOR; MESSENGER RNA; VENTRICULAR MYOSIN;

ANIMAL; ARTICLE; CARDIOMEGALY; DISEASE MODEL; FEMALE; GENETICS; NEWBORN; PREGNANCY; PREGNANCY DIABETES MELLITUS; RAT; SPRAGUE DAWLEY RAT; TIME;

ACTINS; ANIMALS; ANIMALS, NEWBORN; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; DISEASE MODELS, ANIMAL; FEMALE; PREGNANCY; PREGNANCY IN DIABETICS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS; VENTRICULAR MYOSINS;

EID: 20144378339     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951104005062     Document Type: Article

References (28)

1. Towbin JA, Lipshultz SE. Genetics of neonatal cardiomyopathy. Curr Opin Cardiol 1999; 14: 250-262.
2. Lilien LD, Lilien RH, Setrakian S. Hemopericardium and cardiac tamponade as presenting findings of dexamethasone-induced hypertrophic cardiomyopathy complicated by transmural myocardial infarction. Pediatr Cardiol 2003; 24: 280-283.
3. Bensky AS, Kothadia JM, Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics 1996; 97: 818-821.
4. Weintrob N, Karp M, Hod M. Short- and long-range complications in offspring of diabetic mothers. J Diabetes Complications 1996; 10: 294-301.
5. Yunis KA, Bitar FF, Hayek P, Mroueh SM, Mikati M. Transient hypertrophic cardiomyopathy in the newborn following multiple doses of antenatal corticosteroids. Am J Perinatol 1999; 16: 17-21.
6. Miller HC, Wilson HM. Macrosomia, cardiac hypertrophy, erythroblastosis and hyperplasia of the islets of Langerhans in infants born to diabetic mothers. J Pediatr 1943; 23: 251-266.
7. Farquhar JW. The child of the diabetic woman. Arch Dis Child 1959; 34: 76-96.
8. Garner P. Type I diabetes mellitus and pregnancy. Lancet 1995; 346: 157-161.
9. Loffredo CA, Wilson PD, Ferencz C. Maternal diabetes: an independent risk factor for major cardiovascular malformations with increased mortality of affected infants. Teratology 2001; 64: 98-106.
10. Zielinsky P, da Costa MH, Oliveira LT, Bonow FP, da Silva NI, Hagemann LL. Natural history of myocardial hypertrophy and its association with hyperinsulinism in infants of diabetic mothers. Arq Bras Cardiol 1997; 69: 389-394.
11. Lesnik JJ, Singh GK, Balfour IC, Wall DA. Steroid-induced hypertrophic cardiomyopathy following stem cell transplantation in a neonate: a case report. Bone Marrow Transplant 2001; 27: 1105-1108.
12. Takino Y, Iwasaki T, Suzuki T. The cardiomyopathy in infants of streptozotocin-induced diabetic female rats. Jpn Circ J 1990; 54: 1554-1562.
13. Muangmingsuk S, Ingram P, Gupta MP, Arcilla RA, Gupta M. Dexamethasone induced cardiac hypertrophy in newborn rats is accompanied by changes in myosin heavy chain phenotype and gene transcription. Mol Cell Biochem 2000; 209: 165-173.
14. Menezes HS, Barra M, Bello AR, Martins CB, Zielinsky P. Fetal myocardial hypertrophy in an experimental model of gestational diabetes. Cardiol Young 2001; 11: 609-613.
15. Schwartz K, Carrier L, Chassagne C, Wisnewsky C, Boheler KR. Regulation of myosin heavy chain and actin isogenes during cardiac growth and hypertrophy. Symp Soc Exp Biol 1992; 46: 265-272.
16. Vikstrom KL, Bohlmeyer T, Factor SM, Leinwand LA. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 1998; 82: 773-778.
17. Lim HW, De Windt LJ, Mante J, et al. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol 2000; 32: 697-709.
18. Sussman MA, Lim HW, Gude N, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998; 281: 1690-1693.
19. Yu B, Pugazhenthi S, Khandelwal RL. Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes. Biochem Pharmacol 1994; 48: 949-954.
20. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumptionfree analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 2003; 339: 62-66.
21. Livak KJ. ABI Prism 7700 Sequence Detection System. User Bulletin 2: Applied Biosystem, 2001, pp 2-36.
22. Lisowski LA, Verheijen PM, De Smedt MM, Visser GH, Meijboom EJ. Altered fetal circulation in type-1 diabetic pregnancies. Ultrasound Obstet Gynecol 2003; 21: 365-369.
23. Wentzel P, Ejdesjo A, Eriksson UJ. Maternal diabetes in vivo and high glucose in vitro diminish GAPDH activity in rat embryos. Diabetes 2003; 52: 1222-1228.
24. Patel P, Boyd CA, Johnston DG, Williamson C. Analysis of GAPDH as a standard for gene expression quantification in human placenta. Placenta 2002; 23: 697-698.
25. Zhong H, Simons JW. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 1999; 259: 523-526.
26. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999; 270: 41-49.
27. Boheler KR, Carrier L, Chassagne C, de la Bastie D, Mercadier JJ, Schwartz K. Regulation of myosin heavy chain and actin isogenes expression during cardiac growth. Mol Cell Biochem 1991; 104: 101-107.
28. Day DA, Tuite MF. Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J Endocrinol 1998; 157: 361-371.